Embecta Corp. (EMBC) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, Embecta Corp.'s filing signal turned positive.

Embecta Corp. is a global medical device company dedicated to improving the lives of individuals with diabetes. The company offers a comprehensive portfolio of insulin administration products, including conventional and safety pen needles, as well as conventional and safety insulin syringes. These products are designed for use with widely available insulin pen injectors and insulin vials, respectively, and incorporate safety features to prevent needlestick injuries. Embecta's global operations span three manufacturing sites in Ireland, the United States, and China, enabling distribution to over 100 countries through retail, hospital, and pharmacy channels. The company focuses on product quality, clinical innovation, and competitive pricing to maintain its market position.

Revenue is primarily driven by the sale of pen needles, which accounted for approximately 73% of total net revenues in fiscal year 2025. Other revenue sources include sales of syringes and other diabetes management products.